# A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

> **NCT03150862** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene USA, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Pamiparib
- **DRUG:** TMZ
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03150862
- **Lead sponsor:** BeiGene USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-24
- **Primary completion:** 2021-03-17
- **Final completion:** 2021-03-17
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150862, "A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03150862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*